Chimerix Inc. (NASDAQ:CMRX) traded down 3.8% on Thursday . The stock traded as low as $4.01 and last traded at $4.02, with a volume of 247,170 shares traded. The stock had previously closed at $4.18.

Several equities research analysts have weighed in on the company. FBR & Co reissued a “hold” rating on shares of Chimerix in a research note on Sunday, July 17th. Zacks Investment Research lowered Chimerix from a “buy” rating to a “hold” rating in a report on Thursday, May 12th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $16.98.

The firm’s market cap is $185.78 million. The stock has a 50-day moving average price of $3.94 and a 200 day moving average price of $5.37.

Chimerix (NASDAQ:CMRX) last announced its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.66) by $0.09. The firm had revenue of $1.20 million for the quarter, compared to analyst estimates of $2.79 million. On average, analysts anticipate that Chimerix Inc. will post ($2.06) EPS for the current year.

In related news, Director Ernest Mario bought 10,000 shares of the company’s stock in a transaction that occurred on Friday, May 13th. The stock was purchased at an average price of $4.53 per share, for a total transaction of $45,300.00. Following the acquisition, the director now owns 331,440 shares of the company’s stock, valued at $1,501,423.20. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO M Michelle Berrey bought 13,188 shares of the company’s stock in a transaction that occurred on Friday, June 24th. The stock was bought at an average price of $3.69 per share, with a total value of $48,663.72. Following the acquisition, the chief executive officer now directly owns 258,821 shares in the company, valued at approximately $955,049.49. The disclosure for this purchase can be found here.

A number of hedge funds recently bought and sold shares of the stock. Morgan Stanley increased its stake in Chimerix by 96.7% in the fourth quarter. Morgan Stanley now owns 187,163 shares of the biopharmaceutical company’s stock valued at $1,674,000 after buying an additional 92,005 shares during the period. Trexquant Investment LP increased its stake in Chimerix by 453.5% in the fourth quarter. Trexquant Investment LP now owns 131,184 shares of the biopharmaceutical company’s stock valued at $1,174,000 after buying an additional 107,484 shares during the period. Finally, Jennison Associates LLC increased its stake in Chimerix by 67.9% in the fourth quarter. Jennison Associates LLC now owns 1,273,779 shares of the biopharmaceutical company’s stock valued at $11,400,000 after buying an additional 515,029 shares during the period.

Chimerix, Inc a biopharmaceutical company dedicated to discovering, developing and commercializing oral antivirals. The Company’s lipid conjugate technology has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development. It is clinical-stage nucleotide analog lipid-conjugate which has demonstrated potent antiviral activity and safety in convenient, orally administered dosing regimens.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.